Obstet Gynecol Sci.  2014 Nov;57(6):484-491. 10.5468/ogs.2014.57.6.484.

Survival outcomes and toxicity of intraoperative intraperitoneal chemotherapy in advanced epithelial ovarian cancer

• Yoon JY
• Koo YJ
• Kim MJ
• Kim TJ
• Lim KT
• Lee KH

• KMID: 2314015
• DOI: http://doi.org/10.5468/ogs.2014.57.6.484

Abstract

OBJECTIVE
To assess the effect of single-dose cisplatin intraperitoneally administered during cytoreductive surgery in advanced epithelial ovarian cancer.
METHODS
Data from patients who underwent surgical management followed by intravenous (IV) chemotherapy for stage III epithelial ovarian cancer from 2003 to 2012 were retrospectively reviewed. Subjects were divided into intraperitoneal (IP) and no-intraperitoneal (NIP) groups according to the administration of IP cisplatin 100 mg during the staging surgery. Clinical results such as survival outcomes and chemotherapeutic toxicity were compared between the two groups.
RESULTS
Thirty-seven patients in the IP group and 26 in the NIP group were identified. There were no significant differences between the two groups in basic characteristics such as age, histology, and surgical procedures. After the surgery with or without IP chemotherapy, there was no difference in the rate of either hematologic or gastrointestinal toxicity or in the rate of incompletion of following IV chemotherapy. Tumor recurrence occurred in 67.6% (25 patients) of IP group and 57.7% (15 patients) of NIP group (P=0.423) during the mean follow-up period of 37 months. The 3-year disease free-survival rate was 39.9% in the IP group and 35.8% in the NIP group, and the relative risk of recurrence was 0.864 (95% confidence interval, 0.447-1.673; P=0.665) in the IP group as compared with the NIP group.
CONCLUSION
IP chemotherapy with single-dose cisplatin during cytoreductive surgery is safe and feasible with little chemotherapeutic toxicity in advanced epithelial ovarian cancer, but no distinct improvement in survival could be demonstrated in the present study.

Keyword

Intraperitoneal chemotherapy; Ovarian neoplasms; Survival outcome; Toxicity

MeSH Terms

Cisplatin
Drug Therapy*
Follow-Up Studies
Humans
Ovarian Neoplasms*
Recurrence
Retrospective Studies
Cisplatin

Figure

• 

  Fig. 1 Kaplan-Meier analysis shows disease-free survival (DFS) and overall survival (OS) among the 63 eligible patients with stage III epithelial ovarian cancer who were treated with cytoreductive surgery followed by intravenous chemotherapy with or without intraperitoneal (IP) chemotherapy. The 3-year DFS (A) was 39.9% in the IP group and 35.8% in the no-intraperitoneal (NIP) group, and the 3-year OS (B) was 78.5% in the IP group and 79.2% in the NIP group. The median DFS was 21.0 months in both the IP and NIP groups (P=0.659). The median OS was 77.0 months in the IP group and it was not reached in the NIP group (P=0.435).

Reference

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63:11–30.

2. Statistics Korea. Cancer incidence [Internet]. Daejeon: Statistics Korea;2012. cited 2013 Jan 10. Available from: http://kostat.go.kr/portal/korea/index.action.

3. Esselen KM, Rodriguez N, Growdon W, Krasner C, Horowitz NS, Campos S. Patterns of recurrence in advanced epithelial ovarian, fallopian tube and peritoneal cancers treated with intraperitoneal chemotherapy. Gynecol Oncol. 2012; 127:51–54.

4. Dedrick RL, Myers CE, Bungay PM, DeVita VT Jr. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep. 1978; 62:1–11.

5. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006; 354:34–43.

6. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol. 2001; 19:1001–1007.

7. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 1996; 335:1950–1955.

8. National Cancer Institute. NCI clinical announcement: intraperitoneal chemotherapy for ovarian cancer [Internet]. Rockville: National Cancer Institute;c2006. cited 2014 Oct 6. Available from: http://ctep.cancer.gov/highlights/docs/clin_annc_010506.pdf.

9. Ramarajapalli ML, Kilara NG, Subramanyam M, Rao NA. Technique of intraperitoneal chemotherapy using veress needle in patients with ovarian cancer. Int J Gynecol Cancer. 2011; 21:1388–1390.

10. Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2006; (1):CD005340.

11. Walker JL, Armstrong DK, Huang HQ, Fowler J, Webster K, Burger RA, et al. Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 2006; 100:27–32.

12. Deraco M, Virzi S, Iusco DR, Puccio F, Macri A, Famulari C, et al. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study. BJOG. 2012; 119:800–809.

13. Kim MJ, Jung YW, Seong SJ, Yoon BS, Kim ML, Joo WD, et al. Intraoperative intraperitoneal chemotherapy with cisplatin in epithelial ovarian cancer. J Gynecol Oncol. 2012; 23:91–97.

14. Ryu KS, Kim JH, Ko HS, Kim JW, Ahn WS, Park YG, et al. Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer. Gynecol Oncol. 2004; 94:325–332.